ライフサイエンスコーパス: mycophenolic acid

1 lectable marker that conferred resistance to mycophenolic acid.

2 v gene, we generated cell lines resistant to mycophenolic acid.

3 The enzyme was very weakly inhibited by mycophenolic acid.

4 id show some activity, albeit much less than mycophenolic acid.

5 ton pump inhibitors (PPI) reduce exposure of mycophenolic acid.

6 lactone moiety were much less cytotoxic than mycophenolic acid.

7 tions of leflunomide and brequinar sodium or mycophenolic acid.

8 ribosomal stress caused by actinomycin D or mycophenolic acid.

9 vity, the target enzyme of the active moiety mycophenolic acid.

10 cardiovascular disease in patients receiving mycophenolic acid.

11 tly (P=0.001) higher 1-year trough levels of mycophenolic acid (4.16 ng/mL) than cyclosporine-treated

12 rget area under the time-concentration curve-mycophenolic acid: 75 mug.hr/mL).

13 Mycophenolate mofetil did not provide mycophenolic acid absorption as well as EC-MPS.

14 EC-MPS has become the mycophenolic acid agent of choice at this large center.

15 id, were used in the synthesis of monocyclic mycophenolic acid analogues 2a-i.

16 All patients received basiliximab induction, mycophenolic acid and corticosteroids.

17 e Set1-Set3 complex pathway are sensitive to mycophenolic acid and have reduced polymerase levels at

18 s are sensitive to the drugs 6-azauracil and mycophenolic acid and interact genetically with the elon

19 However, the lack of sensitivity to mycophenolic acid and the Km for NAD (1180 microM) exemp

20 effect was abrogated by GTP depletion using mycophenolic acid and was restored upon GTP repletion by

21 vitro bradyzoite formation and treated with mycophenolic acid and xanthine to positively select for

22 selected for by growth in medium containing mycophenolic acid and xanthine.

23 anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously kno

24 teraction was observed between cyclosporine, mycophenolic acid, and RAL.

25 pients treated with alemtuzumab, tacrolimus, mycophenolic acid, and steroids.

26 Exposures to tacrolimus, mycophenolic acid, and total and free prednisolone were

27 toxicity, could be obtained with ribavirin, mycophenolic acid, and viramidine.

28 However, mycophenolic acid, another IMPDH inhibitor, had no antiv

29 ophosphate together with a second inhibitor, mycophenolic acid, are presented here.

30 oglobulin as induction agent, tacrolimus and mycophenolic acid as maintenance therapy.

31 The values of Km for NAD and Ki for mycophenolic acid as well as the synergistic interaction

32 5, and recipients were converted from CsA to mycophenolic acid at 6 months posttransplantation.

33 itors of this enzyme such as 6-azauracil and mycophenolic acid, at least partly because of their inab

34 5), acute rejection (AHR, 5.4; P<0.001), and mycophenolic acid AUC0-12 hr more than 50 hr mg/L (AHR,

35 in a negatively cooperative fashion and that mycophenolic acid binding is critically dependent on the

36 ffects of substrate, product, and inhibitor (mycophenolic acid) binding on the conformation and stabi

37 ofiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK-506 provide a p

38 rst, depletion of GTP by treating cells with mycophenolic acid decreased the level of NS without appa

39 sformants were isolated under selection with mycophenolic acid, demonstrating the feasibility of HXGP

40 The use of mycophenolic acid did not impact on the response to riba

41 The proportion of patients receiving mycophenolic acid dose equal to or more than 2000 mg per

42 ced by overlapping toxicity with concomitant mycophenolic acid, exploration of alternative adjunctive

43 In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 microgh/ml) experien

44 It is possible that a reduction in mycophenolic acid exposure contributed to the increased

45 The defined higher mycophenolic acid exposure was well tolerated.

46 g rat islets in the presence of 25 microg/ml mycophenolic acid for 20 h.

47 the rate and extent of absorption of SRL and mycophenolic acid from EC-MPS were similar.

48 Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clinical utility for the treatmen

49 nosine monophosphate dehydrogenase inhibitor mycophenolic acid have been explored.

50 ) = 0.1 microM, respectively) as potently as mycophenolic acid (IC(50) = 0.3 microM).

51 ntly than tiazofurin (IC50 = 12.4 microM) or mycophenolic acid (IC50 = 7.7 microM).

52 sodium in the MLC, and from cyclosporine and mycophenolic acid in both MLC and CTLL-4.

53 ive a compound with 2-4 times the potency of mycophenolic acid in vitro and in vivo.

54 mational changes occur during the normal and mycophenolic acid-inhibited reaction sequences of IMPDH.

55 Mycophenolic acid inhibition appeared to impart even gre

56 pronounced resistance of C. parvum IMPDH to mycophenolic acid inhibition is in strong agreement with

57 We propose that mycophenolic acid inhibits IMPDH by trapping a transient

58 Plasma-free mycophenolic acid levels of 10 to 30 microg/mL were asso

59 nsplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is repor

60 maintenance for 3 months and then sirolimus-mycophenolic acid maintenance thereafter.

61 oup of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppre

62 The 10 cases were treated with azathioprine, mycophenolic acid, methotrexate, or infliximab.

63 reduced-exposure cyclosporine A (CsA) or to mycophenolic acid (MPA) 1.44 g per day plus standard-exp

64 mainly related to immunosuppressive drugs as mycophenolic acid (MPA) and anti-infectious agents, but

65 their lower affinity for inhibitors such as mycophenolic acid (MPA) and thiazole-4-carboxamide adeni

66 pients were concentration controlled to keep mycophenolic acid (MPA) C0 levels at 1.8-4 microg/ml.

67 /d and dose adjusted from day 5 according to mycophenolic acid (MPA) exposure (arm A) or a regimen wi

68 Previous studies have shown that mycophenolic acid (MPA) has an anti-HCV activity.

69 ehydrogenase (IMPDH) in complex with IMP and mycophenolic acid (MPA) has been determined by X-ray dif

70 rmined, and the inhibitory effect of XMP and mycophenolic acid (MPA) has been studied.

71 The immunosuppressant agent mycophenolic acid (MPA) has shown clinical efficacy for

72 by tacrolimus, everolimus, prednisolone, and mycophenolic acid (MPA) in clinically relevant concentra

73 this issue of Blood, Nguyen et al show that mycophenolic acid (MPA) induces GTP depletion, which inh

74 Mycophenolic acid (MPA) is a highly effective immunosupp

75 Mycophenolic acid (MPA) is a potent and specific inhibit

76 Mycophenolic acid (MPA) is a potent inhibitor of mammali

77 Mycophenolic acid (MPA) is a species-specific inhibitor

78 Mycophenolic acid (MPA) is an inhibitor of lymphocyte pr

79 Mycophenolic acid (MPA) is the active immunosuppressive

80 Mycophenolic acid (MPA) is the active metabolite of myco

81 echanisms underlying the negative effects of mycophenolic acid (MPA) on human intestinal cells.

82 independent PKC isoforms, in comparison with mycophenolic acid (MPA) on rat renal transplants with pr

83 The mycophenolic acid (MPA) preparations are one of the most

84 rations of tacrolimus/cyclosporine (CsA) and mycophenolic acid (MPA) singly or in combination had no

85 cs, PD) in allograft recipients treated with mycophenolic acid (MPA) to determine its mechanisms and

86 t biopsies (n=246), and serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated.

87 Tacrolimus (TAC) and mycophenolic acid (MPA) trough levels were measured from

88 ultaneously in the synthesis of analogues of mycophenolic acid (MPA) was explored.

89 ylprednisolone (MP), methotrexate (MTX), and mycophenolic acid (MPA) were added to the final 6 days o

90 Control groups received mycophenolic acid (MPA) with standard-dose cyclosporine.

91 We have examined the effects of mycophenolic acid (MPA), a potent IMPDH inhibitor, on th

92 The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine m

93 Mycophenolic acid (MPA), a selective inhibitor of inosin

94 have examined the induction of apoptosis by mycophenolic acid (MPA), a specific IMPDH inhibitor, in

95 . albicans cells is inhibited at 1 microg of mycophenolic acid (MPA), a specific inhibitor of IMP deh

96 We have demonstrated that mycophenolic acid (MPA), a specific inosine monophosphat

97 Mycophenolic acid (MPA), an immunosuppressive drug, was

98 Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogena

99 Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5'-mono

100 This activity is shared by mycophenolic acid (MPA), an inhibitor of purine biosynth

101 ponses were inhibited by tacrolimus (FK506), mycophenolic acid (MPA), and cyclosporine (CsA) in a dos

102 splant recipients on calcineurin inhibitors, mycophenolic acid (MPA), and prednisone with IFTANOS, su

103 BEL, mycophenolic acid (MPA), and sirolimus, either alone or

104 ophosphate dehydrogenase inhibitors, such as mycophenolic acid (MPA), induce the differentiation of P

105 prototypic uncompetitive inhibitor of IMPDH, mycophenolic acid (MPA), is the active form of mycopheno

106 Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is widely used as an immunosupp

107 equency was measured in the presence of RBV, mycophenolic acid (MPA), selenazofurin, or tiazofurin.

108 We evaluated plasma concentrations of mycophenolic acid (MPA), the active metabolite of MMF, a

109 Here, we studied the effect of mycophenolic acid (MPA), the active metabolite of mycoph

110 ith its substrate IMP, IMP and the inhibitor mycophenolic acid (MPA), the product XMP with MPA, and X

111 rostate PC-3 tumor cell line as a target and mycophenolic acid (MPA), tiazofurin, or ribavirin, which

112 ote the delivery of a model immunomodulator, mycophenolic acid (MPA), to the lymphatic system after o

113 ined by reduction of the carboxylic group of mycophenolic acid (MPA), was coupled with 2',3'-O-isopro

114 ompactum produces the immunosuppressive drug mycophenolic acid (MPA), which is a potent inhibitor of

115 rapidly hydrolyzed to its active metabolite mycophenolic acid (MPA), which is excreted by the kidney

116 ch was previously identified as resistant to mycophenolic acid (MPA).

117 e turnover events accompanying inhibition by mycophenolic acid (MPA).

118 ibition of purine nucleotide biosynthesis by mycophenolic acid (MPA).

119 g delivery vehicle for the immunosuppressant mycophenolic acid (MPA).

120 itation, and the IMP dehydrogenase inhibitor mycophenolic acid (MPA).

121 gan transplantation, is a prodrug to deliver mycophenolic acid (MPA).

122 en and experimental drug therapies including mycophenolic acid (MPA).

123 idney transplant patients in the prospective Mycophenolic Acid Observational Renal Transplant registr

124 ta do not demonstrate a consistent effect of mycophenolic acid on dnDSA production.

125 Mycophenolic acid or doxorubicin induced NS degradation

126 nce of pharmacological concentrations FK506, mycophenolic acid, or cyclosporine-A.

127 f RTF1 causes sensitivity to 6-azauracil and mycophenolic acid, phenotypes correlated with a transcri

128 4 week surveillance and subsequent as needed mycophenolic acid predose concentrations during the firs

129 intenance immunosuppression with tacrolimus, mycophenolic acid prodrugs, and prednisone.

130 ucted to evaluate risks for BPAR relating to mycophenolic acid product.

131 The drugs 6-azauracil and mycophenolic acid reduce both the elongation rate and pr

132 A common strategy to mitigate mycophenolic acid-related GI adverse events includes dos

133 contain the HIV-1 genome with the bacterial mycophenolic acid resistance gene gpt in place of the vi

134 the NOT4 gene elicited 6-azauracil (6AU) and mycophenolic acid sensitivities, hallmarks of transcript

135 rium is perturbed in the presence of IMP and mycophenolic acid, suggesting a mechanism for the ligand

136 Addition of clinically relevant levels of mycophenolic acid, the active agent for MMF, added to mo

137 hate (IMP), and the uncompetitive inhibitor, mycophenolic acid, to inosine monophosphate dehydrogenas

138 th mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 microg/ml) or

139 reduction of cardiac allograft rejection by mycophenolic acid was accompanied by reduced CD40 ligand

140 e (E)-4-methyl-4-hexenoic acid side chain of mycophenolic acid, were used in the synthesis of monocyc

141 phate dehydrogenase inhibitors ribavirin and mycophenolic acid, which are already in clinical use, sh